Trial Profile
Duration of Protection Based on Persistent Antibody Titers 12-24 Months After Vaccination: Follow Up to Phase 2 Study of Meningococcal Serogroups A, C, Y & W-135 Polysaccharide Diphtheria Toxoid Conjugate Vaccine (NmVac4-A/C/Y/W-135-DT)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 14 Apr 2016
Price :
$35
*
At a glance
- Drugs Meningococcal vaccine groups A C Y W-135 polysaccharide (Primary)
- Indications Meningococcal infections; Meningococcal meningitis
- Focus Adverse reactions
- Sponsors JN-International Medical Corporation
- 11 Apr 2016 Status changed from active, no longer recruiting to completed.
- 20 Jul 2015 New trial record